According to MannKind Corporation, United Therapeutics has exercised an option granted under a 2018 licensing and collaboration agreement between the companies for development of an additional dry powder inhalation product based on MannKind’s Technosphere technology. The 2018 agreement covered development of Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH), as well as research on additional potential molecules for the treatment of PAH.
For the second collaboration, United Therapeutics will pay $5 million up front plus up to $35 million in milestone payments and potential royalties on any net sales. United Therapeutics will also be responsible for preclinical and clinical development of the dry powder formulation, MannKind said.
MannKind CEO Michael Castagna commented, “Building on the success of Tyvaso DPI, we are proud to deepen our collaboration with United Therapeutics to bring innovative patient-centric inhaled therapies to patients living with pulmonary hypertension. This next step highlights the strength of our partnership and the versatility of our dry powder formulations and inhalation devices in addressing serious respiratory conditions.”
Read the MannKind Corporation press release
